What is a stock summary page? Click here for an overview.
Business Description
Matinas BioPharma Holdings Inc
NAICS : 325412
SIC : 2834
ISIN : US5768101058
Description
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.52 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 84.7 | |||||
| 3-Year EBITDA Growth Rate | 4.1 | |||||
| 3-Year EPS without NRI Growth Rate | 3.6 | |||||
| 3-Year FCF Growth Rate | 6.9 | |||||
| 3-Year Book Growth Rate | -33.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.34 | |||||
| 9-Day RSI | 43.64 | |||||
| 14-Day RSI | 44.65 | |||||
| 3-1 Month Momentum % | -16.87 | |||||
| 6-1 Month Momentum % | -82.59 | |||||
| 12-1 Month Momentum % | -94.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.53 | |||||
| Quick Ratio | 5.53 | |||||
| Cash Ratio | 5.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | -318.14 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -1546.9 | |||||
| ROE % | -115.05 | |||||
| ROA % | -88.46 | |||||
| ROIC % | -219.15 | |||||
| 3-Year ROIIC % | -172.27 | |||||
| ROC (Joel Greenblatt) % | -445.49 | |||||
| ROCE % | -102.77 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.09 | |||||
| PB Ratio | 0.17 | |||||
| Price-to-Tangible-Book | 0.23 | |||||
| EV-to-EBIT | 0.23 | |||||
| EV-to-EBITDA | 0.24 | |||||
| EV-to-Revenue | -4.67 | |||||
| EV-to-Forward-Revenue | 61.76 | |||||
| EV-to-FCF | 0.3 | |||||
| Price-to-GF-Value | 0.03 | |||||
| Price-to-Net-Current-Asset-Value | 0.39 | |||||
| Price-to-Net-Cash | 0.45 | |||||
| Earnings Yield (Greenblatt) % | 434.78 | |||||
| FCF Yield % | -632.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:MTNB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Matinas BioPharma Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.096 | ||
| EPS (TTM) ($) | -4.79 | ||
| Beta | 1.4 | ||
| 3-Year Sharpe Ratio | -0.96 | ||
| 3-Year Sortino Ratio | -1.13 | ||
| Volatility % | 90.28 | ||
| 14-Day RSI | 44.65 | ||
| 14-Day ATR ($) | 0.055774 | ||
| 20-Day SMA ($) | 0.55087 | ||
| 12-1 Month Momentum % | -94.81 | ||
| 52-Week Range ($) | 0.4748 - 10.745 | ||
| Shares Outstanding (Mil) | 5.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Matinas BioPharma Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Matinas BioPharma Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Matinas BioPharma Holdings Inc Frequently Asked Questions
What is Matinas BioPharma Holdings Inc(MTNB)'s stock price today?
The current price of MTNB is $0.53. The 52 week high of MTNB is $10.75 and 52 week low is $0.47.
When is next earnings date of Matinas BioPharma Holdings Inc(MTNB)?
The next earnings date of Matinas BioPharma Holdings Inc(MTNB) is 2025-04-10 Est..
Does Matinas BioPharma Holdings Inc(MTNB) pay dividends? If so, how much?
Matinas BioPharma Holdings Inc(MTNB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers